Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening
MSK Discovery Study: Use of cfNA To Distinguish Between Benign and Malignant BI-RADS 4 Radiographic Lesions
Sponsor: GRAIL, Inc.
Listed as NCT03372902, this observational or N/A phase trial focuses on Breast Benign and Breast Cancer and remains completed. Sponsored by GRAIL, Inc., it has been updated 23 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
23 versions recorded-
Apr 2025 — Present [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Feb 2025 — Apr 2025 [monthly]
Active Not Recruiting
-
Sep 2024 — Feb 2025 [monthly]
Active Not Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting
▶ Show 18 earlier versions
-
May 2023 — May 2024 [monthly]
Active Not Recruiting
-
May 2022 — May 2023 [monthly]
Active Not Recruiting
-
Dec 2021 — May 2022 [monthly]
Active Not Recruiting
-
Oct 2021 — Dec 2021 [monthly]
Active Not Recruiting
-
May 2021 — Oct 2021 [monthly]
Active Not Recruiting
-
Apr 2021 — May 2021 [monthly]
Active Not Recruiting
-
Jan 2021 — Apr 2021 [monthly]
Active Not Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting
-
Jun 2020 — Nov 2020 [monthly]
Active Not Recruiting
-
Apr 2020 — Jun 2020 [monthly]
Active Not Recruiting
-
May 2019 — Apr 2020 [monthly]
Active Not Recruiting
-
Apr 2019 — May 2019 [monthly]
Active Not Recruiting
Status: Enrolling By Invitation → Active Not Recruiting
-
Sep 2018 — Apr 2019 [monthly]
Enrolling By Invitation
-
Jun 2018 — Sep 2018 [monthly]
Enrolling By Invitation
Status: Recruiting → Enrolling By Invitation
-
May 2018 — Jun 2018 [monthly]
Recruiting
-
Apr 2018 — May 2018 [monthly]
Recruiting
Phase: NA → None
-
Feb 2018 — Apr 2018 [monthly]
Recruiting NA
-
Dec 2017 — Feb 2018 [monthly]
Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- GRAIL, Inc.
- Memorial Sloan Kettering Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .